Literature DB >> 17525046

Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma.

C Bueno Muiño1, J Puente Vázquez, J Sastre Valera, J A García-Sáenz, M Martín, N García Miralles, A Sánchez-Pernaute, E Díaz-Rubio.   

Abstract

Locally advanced gastric adenocarcinoma has a poor outcome. Neoadjuvant treatment is being tested in locally advanced non-resectable tumours and in those resectable tumours with a high risk of recurrence. Efforts to identify prognostic factors and more active and less toxic preoperative regimens are being searched for. We report the case of a patient achieving a complete histopathological complete response following docetaxel- based neoadjuvant chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17525046     DOI： 10.1007/s12094-007-0063-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  17 in total

1.  Neoadjuvant chemotherapy: a standard treatment for locally advanced gastric cancer in the near future?

Authors:  Junichi Sakamoto
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

2.  European Code Against Cancer and scientific justification: third version (2003).

Authors:  P Boyle; P Autier; H Bartelink; J Baselga; P Boffetta; J Burn; H J G Burns; L Christensen; L Denis; M Dicato; V Diehl; R Doll; S Franceschi; C R Gillis; N Gray; L Griciute; A Hackshaw; M Kasler; M Kogevinas; S Kvinnsland; C La Vecchia; F Levi; J G McVie; P Maisonneuve; J M Martin-Moreno; J Newton Bishop; F Oleari; P Perrin; M Quinn; M Richards; U Ringborg; C Scully; E Siracka; H Storm; M Tubiana; T Tursz; U Veronesi; N Wald; W Weber; D G Zaridze; W Zatonski; H zur Hausen
Journal:  Ann Oncol       Date:  2003-07       Impact factor: 32.976

3.  Prognostic factors after curative resection for gastric cancer. A population-based study.

Authors:  S Msika; A M Benhamiche; J L Jouve; P Rat; J Faivre
Journal:  Eur J Cancer       Date:  2000-02       Impact factor: 9.162

4.  Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.

Authors:  J A Ajani; P F Mansfield; C H Crane; T T Wu; S Lunagomez; P M Lynch; N Janjan; B Feig; J Faust; J C Yao; R Nivers; J Morris; P W Pisters
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

5.  Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival.

Authors:  Dan Green; Sergio Ponce de Leon; Eucario Leon-Rodriguez; Ricardo Sosa-Sanchez
Journal:  Am J Clin Oncol       Date:  2002-02       Impact factor: 2.339

6.  Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).

Authors:  I Songun; H J Keizer; J Hermans; P Klementschitsch; J E de Vries; J A Wils; J van der Bijl; J H van Krieken; C J van de Velde
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

7.  Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.

Authors:  J A Ajani; R J Mayer; D M Ota; G D Steele; D Evans; M Roh; D J Sugarbaker; P Dumas; C Gray; D A Vena
Journal:  J Natl Cancer Inst       Date:  1993-11-17       Impact factor: 13.506

8.  Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.

Authors:  L Leichman; H Silberman; C G Leichman; C P Spears; M Ray; F M Muggia; M Kiyabu; R Radin; L Laine; S Stain
Journal:  J Clin Oncol       Date:  1992-12       Impact factor: 44.544

9.  Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin.

Authors:  H Wilke; P Preusser; U Fink; U Gunzer; H J Meyer; J Meyer; J R Siewert; W Achterrath; L Lenaz; H Knipp
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

10.  Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.

Authors:  Katja Ott; Andreas Sendler; Karen Becker; Hans-Joachim Dittler; Hermann Helmberger; Raimonde Busch; Christian Kollmannsberger; J Rüdiger Siewert; Ulrich Fink
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.